Mid-cap Health Care company Legend Biotech has logged a -1.4% change today on a trading volume of 1,464,636. The average volume for the stock is 1,721,803.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Based in Somerset, United States the company has 2,700 full time employees and a market cap of $6,715,218,432.
The company is now trading -52.17% away from its average analyst target price of $76.29 per share. The 19 analysts following the stock have set target prices ranging from $54.0 to $94.0, and on average give Legend Biotech a rating of buy.
Over the last 12 months LEGN shares have declined by -34.2%, which represents a difference of -53.8% when compared to the S&P 500. The stock's 52 week high is $59.62 per share and its 52 week low is $27.34. Based on Legend Biotech's average net margin growth of 27.5% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2025 | 195,053 | -100,916 | -52 | -85.71 |
| 2024 | 627,241 | -177,026 | -28 | 84.62 |
| 2023 | 285,143 | -518,254 | -182 | 52.23 |
| 2022 | 117,005 | -446,349 | -381 | 34.98 |
| 2021 | 68,826 | -403,582 | -586 | -65.07 |
| 2020 | 75,000 | -266,373 | -355 |
